Swab sample nucleic acid releasing agent
By combining the components such as strong alkali, SDS, enzyme protector and treluton 100 in the nucleic acid release agent, the problems of inconvenience and inaccurate release in the prior art are solved, and the rapid release of nucleic acids and simple operation are achieved, reducing false Negative results are suitable for the detection of low-concentration samples.
Patent Information
- Application Number
- CN202411188117.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-28
- Publication Date
- 2024-12-06
AI Technical Summary
The existing nucleic acid release agents are not easy to operate and are not released quickly enough, making it difficult to meet the detection needs of low-concentration samples, resulting in too many false negative results.
By combining the nucleic acid release agent with strong alkali, SDS, enzyme protectant and treluton 100 components, a swab sample nucleic acid release agent can quickly release DNA or RNA. The sample is mixed with the release agent and stands at room temperature. Nucleic acid testing can be performed without affecting subsequent PCR reactions.
It realizes rapid release of nucleic acid, simplifies operation, increases sample loading, and reduces false negative results. It is suitable for nucleic acid testing in emergency and fever clinics.
Smart Images

Figure BDA0005014142760000051 
Figure BDA0005014142760000061 
Figure BDA0005014142760000071
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of nucleic acid detection, and in particular to a swab sample nucleic acid releaser. Background Art
[0002] Conventional nucleic acid detection of pathogenic microorganisms requires a nucleic acid extraction step, which makes the nucleic acid detection process time-consuming and cannot meet the needs of rapid detection. Nucleic acid releasers can be used to quickly lyse various common samples without the need for nucleic acid extraction and purification steps. Sample lysates can be directly used as templates for amplification reactions. They are currently widely used in the field of pathogenic microorganism detection. However, existing nucleic acid releasers have problems such as not being easy to operate and not releasing nucleic acids quickly enough.
[0003] Assume that a certain nucleic acid detection method is sensitive enough, that is, a positive result can be reported if there is more than or equal to one target molecule in the detection system. At this time, for low-concentration samples (≤3copy / μL), the stability of the detection results depends to a large extent on whether more than or equal to one target molecule can be obtained to enter the detection system for amplification. For nucleic acid detection, the sampling of low-concentration samples is a random and independent event, and the number of target molecules obtained during each sampling process obeys the Poisson distribution. From the perspective of sampling probability, the Poisson distribution is used to explain the reason for the instability of low-concentration sample detection, and the probability of obtaining k (non-negative integer) target molecules under different sampling volumes of low-concentration samples (1copy / μL) is calculated. Only when the sampling volume reaches 10ul, there is a 99.72% probability of obtaining ≥3copy of the virus. Chinese patent CN112980831B discloses a swab nucleic acid releaser. Although it is simple and convenient, its sample volume can only reach 20% of the reaction volume, which may not meet the detection requirements of low-concentration samples and will cause many false negatives.
[0004] Therefore, in the current context, the continuous development and optimization of nucleic acid releasers is of great significance for the actual detection of pathogenic microorganisms. Summary of the invention
[0005] The purpose of the present invention is to overcome the shortcomings of the nucleic acid releaser products described in the above-mentioned background technology, and provide a swab sample nucleic acid releaser, which can quickly release the nucleic acid of the swab sample DNA or RNA. After the sample is collected, the sample is immediately mixed with the nucleic acid releaser and left to stand at room temperature for 230 minutes. The sample can be aspirated for nucleic acid testing without affecting the subsequent PCR detection reaction. The operation is simple and the method is particularly suitable for nucleic acid testing in some scenarios such as emergency departments and fever clinics.
[0006] In order to achieve the purpose of the present invention, the present invention has compounded a variety of cell lysis agents in the nucleic acid releaser through a large number of research experiments. The main components of the swab sample nucleic acid releaser finally obtained are strong alkali, SDS, enzyme protectant and Triton 100 (Triton-100). The test results show that the nucleic acid releaser of the present invention can achieve the requirement of rapid release of nucleic acid without affecting the subsequent PCR reaction.
[0007] Furthermore, in some embodiments of the present invention, the strong base in the nucleic acid releasing agent is NaOH and / or KOH.
[0008] Furthermore, in some embodiments of the present invention, the concentration of the strong base in the nucleic acid releasing agent is 10-30 mM.
[0009] Furthermore, in some embodiments of the present invention, the mass concentration of SDS in the nucleic acid releasing agent is 0.005% to 0.05%.
[0010] Furthermore, in some embodiments of the present invention, the volume concentration of Triton 100 in the nucleic acid releasing agent is 2% to 6%, preferably 2% to 4%.
[0011] Furthermore, in some embodiments of the present invention, the enzyme protectant is selected from one or more of gelatin, tween 20 or betaine.
[0012] Preferably, in some embodiments of the present invention, the content of the enzyme protectant in the nucleic acid releasing agent is 2% to 6%, preferably 4%.
[0013] Further preferably, in some embodiments of the present invention, the concentration of strong base in the nucleic acid releaser is 10-20 mM, the mass concentration of SDS is 0.008% to 0.012%, the mass volume concentration of Triton 100 is 2% to 4%, and the content of enzyme protectant is 2% to 6%.
[0014] More preferably, in some embodiments of the present invention, the strong base in the nucleic acid releaser is NaOH, and the enzyme protectant is tween20.
[0015] Further preferably, in some embodiments of the present invention, the enzyme protectant is tween 20 and gelatin, and the mass ratio of the two is 4:0.2-0.6.
[0016] Compared with the prior art, the advantages of the present invention are as follows:
[0017] (1) The main component of conventional nucleic acid extraction reagents is a cell lysis agent. The residues of commonly used cell lysis agents such as urea and CTAB will significantly inhibit the subsequent PCR reaction, and the amount used needs to be strictly controlled. In addition to the above reagents, some relatively mild surfactants can also meet the needs of cell lysis. The nucleic acid release agent of the present invention is compounded with a variety of cell lysis agents, which can not only quickly release nucleic acids, but also have no adverse effects.
[0018] (2) The nucleic acid releaser of the present invention can quickly release nucleic acid from the collected swab sample. After the sample is collected, the sample is immediately mixed with the nucleic acid releaser and allowed to stand at room temperature for 2 to 30 minutes. The sample lysate can then be aspirated for nucleic acid detection. The operation is convenient and quick, and will not affect the subsequent PCR reaction. The sample addition amount can reach the maximum reaction volume capacity. DETAILED DESCRIPTION
[0019] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with embodiments. Additional aspects and advantages of the present invention will be given in part in the following description, and part will become apparent from the following description, or will be understood through the practice of the present invention. It should be understood that the following description is only used to explain the present invention and is not intended to limit the present invention.
[0020] As used herein, the terms "comprises," "including," "having," "containing," or any other variation thereof, are intended to cover a non-exclusive inclusion. For example, a composition, process, method, article, or apparatus that comprises the listed elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such composition, process, method, article, or apparatus.
[0021] When amount, concentration or other value or parameter is expressed as range, preferred range or a series of upper preferred value and lower preferred value limit range, this should be understood as specifically disclosing all ranges formed by any pairing of any range upper limit or preferred value and any range lower limit or preferred value, regardless of whether the range is disclosed separately. For example, when disclosing range "1 to 5", described range should be interpreted as including range "1 to 4", "1 to 3", "1 to 2", "1 to 2 and 4 to 5", "1 to 3 and 5" etc. When numerical range is described in this article, unless otherwise stated, the range is intended to include its end value and all integers and fractions within the range.
[0022] Singular forms include plural references unless the context clearly indicates otherwise. "Optional" or "either" means that the subsequently described event or incident may or may not occur, and that the description includes instances where the event occurs and instances where it does not.
[0023] The indefinite articles "a" and "an" before the elements or components of the present invention have no limitation on the quantity requirements (i.e. the number of occurrences) of the elements or components. Therefore, "a" or "an" should be interpreted as including one or at least one, and the elements or components in the singular form also include the plural form, unless the quantity obviously refers to the singular form only.
[0024] In addition, the descriptions of the terms "one embodiment", "some embodiments", "examples", "specific examples", or "some examples" described below mean that the specific features, structures, materials, or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic expressions of the above terms do not necessarily refer to the same embodiment or example. Moreover, the technical features involved in the various embodiments of the present invention can be combined with each other as long as they do not conflict with each other.
[0025] Example 1: NaOH achieves the effect of cracking samples
[0026] Strong alkaline solution can break the cell membrane and achieve the effect of nucleic acid release, but high concentration of alkali will inhibit downstream PCR. Reduce the concentration of the alkaline solution, and it will not inhibit downstream PCR at a concentration with a certain lysis effect. The alkaline solution can be KOH or NaOH. The samples use HSV standard and negative genital swab samples, and use 1mL sterile water to prepare a certain concentration of NaOH solution to obtain releasers 1 to 5, and use aqueous solution as a control. The reagent uses a self-built 25ul freeze-dried HSV1 amplification reagent. The operation method is to take 28 negative vaginal swab samples and rinse them into 1mL releasers 1 to 5 for shaking and mixing, and then add HSV standards to each releaser to simulate real clinical positive genital swab samples, shake and mix them for 10 minutes, take 25μL and add it to 25μL freeze-dried powder amplification reagent, and then re-dissolve it and directly perform amplification reaction in a rapid amplification instrument.
[0027] Table 1
[0028] Detection items NaOH Ct-Repeat 1 Ct-Repeat 2 Ct-Repeat 3 Release Agent 1 10mM 34.07 33.39 32.34 Release Agent 2 20mM 32.47 33.11 32.23 Release Agent 3 30mM 35.73 36.48 34.50 Release Agent 4 40mM 38.14 39.14 0.00 Release Agent 5 50mM 39.52 0.00 0.00
[0029] The results are shown in Table 1. When the concentration of the strong base in the release agent is between 10 and 30 mM, there are different degrees of sample lysis effects. When it exceeds 40 mM, it will affect the stability of the amplification.
[0030] Example 2 Combination of SDS and tween20 to achieve sample lysis effect
[0031] Tween20 can form micelles to absorb SDS and allow enzyme reaction. SDS at a certain concentration mixed with tween20 can achieve the effect of lysis without inhibiting downstream amplification. The samples used HSV standard and negative genital swab samples, and a certain concentration of SDS and Tween20 mixture was prepared with 1mL of sterile water to obtain releasers 1 to 10. The reagent used was a self-built 25ul freeze-dried HSV1 amplification reagent. The operation method was to take 10 negative vaginal swab samples and rinse them into 1mL of releasers 1 to 10, and then add HSV standard to each releaser to simulate the real clinical positive genital swab sample, shake and mix, let it stand for 1 minute, take 25μL and add it to 25μL of freeze-dried powder amplification reagent, and then re-dissolve it and directly perform amplification reaction in a rapid amplification instrument.
[0032] Table 2
[0033]
[0034]
[0035] The results are shown in Table 2. When the SDS concentration in the release agent is 0.005% to 0.05% and the Tween20 concentration is 2% to 6%, there are different degrees of sample lysis effects and the inhibitory effect of SDS on PCR amplification can be weakened.
[0036] Example 3 Combination of SDS and gelatin to achieve sample lysis effect
[0037] Gelatin is a peptide molecule polymer that can improve the stability of Taq DNA polymerase. By adding gelatin, we try to achieve the effect of cleavage without inhibiting downstream amplification. The samples used HSV standard and negative genital swab samples, and a certain concentration of SDS and gelatin mixture was prepared with 1mL of sterile water to obtain releasers 1-6. The reagent used was a self-made 25ul freeze-dried HSV1 amplification reagent. The operation method was to take 10 negative vaginal swab samples and rinse them into 1mL of releasers 1-6 and shake and mix them, and then add HSV standard to each releaser to simulate the real clinical positive genital swab sample, shake and mix it for 1 minute, take 25μL and add it to 25μL of freeze-dried powder amplification reagent, and then re-dissolve it and directly perform amplification reaction in a rapid amplification instrument.
[0038] Table 3
[0039] Detection items NaOH SDS gelatin Ct-Repeat 1 Ct-Repeat 2 Ct-Repeat 3 Release Agent 1 20mM 0.01% 0.2% 0 0 39.24 Release Agent 2 20mM 0.01% 0.4% 38.15 0 0 Release Agent 3 20mM 0.01% 0.6% 0 0 0 Release Agent 4 20mM 0.005% 0.2% 38.56 39.29 0 Release Agent 5 20mM 0.005% 0.4% 38.76 37.59 39.44 Release Agent 6 20mM 0.005% 0.6% 39.32 0 38.66
[0040] The results are shown in Table 3. When SDS exists in the releasing agent, using gelatin alone as an enzyme protectant cannot completely eliminate the inhibitory effect of SDS on the amplification reaction.
[0041] Example 4 Combination of SDS, tween 20 and gelatin to achieve sample lysis effect
[0042] The samples used were HSV standard and negative genital swab samples. A certain concentration of SDS, tween20 and gelatin mixture was prepared with 1 mL of sterile water to obtain releasers 1-3. The reagent used was self-made 25 ul freeze-dried HSV1 amplification reagent. The operation method was to take 10 negative vaginal swab samples and rinse them into 1 mL of releasers 1-3 respectively, and shake and mix them. Then, HSV standard was added to each releaser to obtain a simulated real clinical positive genital swab sample. The mixture was shaken and allowed to stand for 1 minute. 25 μL was taken and added to 25 μL of freeze-dried powder amplification reagent. After reconstitution, the amplification reaction was directly performed in a rapid amplification instrument.
[0043] Table 4
[0044] Detection items NaOH SDS Tween20 gelatin Ct-Repeat 1 Ct-Repeat 2 Ct-Repeat 3 Release Agent 1 20mM 0.01% 4% 0.2% 29.14 30.37 29.62 Release Agent 2 20mM 0.01% 4% 0.4% 28.33 29.25 28.66 Release Agent 3 20mM 0.01% 4% 0.6% 30.52 31.45 29.55
[0045] The results are shown in Table 4. When the enzyme protectants are used in combination, the inhibitory effect of SDS on the amplification reaction can be further eliminated.
[0046] Example 5 Detection of different concentrations of triton 100 to improve sample lysis ability
[0047] The samples used HSV standard and negative genital swab samples, and a certain concentration of triton100 mixed solution was prepared with 1mL of sterile water to obtain releasers 1-4. The reagent used was self-made 25ul freeze-dried HSV1 amplification reagent. The operation method was to take 4 negative vaginal swab samples and rinse them into 1mL of releasers 1-4 respectively, and shake and mix them. Then, HSV standard was added to each releaser to obtain a simulated real clinical positive genital swab sample, shake and mix it for 1 minute, take 25μL and add it to 25μL of freeze-dried powder amplification reagent, and after reconstitution, directly perform amplification reaction in a rapid amplification instrument.
[0048] Table 5
[0049]
[0050]
[0051] The results are shown in Table 5. When the concentration of Triton100 in the release agent is 2-4%, it is most suitable. When it reaches 6%, it has a certain inhibitory effect on amplification.
[0052] It will be easily understood by those skilled in the art that the above description is merely an example of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A swab sample nucleic acid release agent, It is characterized in that The nucleic acid releaser comprises a strong base, SDS, an enzyme protectant and Triton 100.
2. The swab sample nucleic acid releaser according to claim 1, It is characterized in that The strong base in the nucleic acid releaser is NaOH and / or KOH.
3. The swab sample nucleic acid releaser according to claim 1, It is characterized in that The concentration of the strong base in the nucleic acid releaser is 10-30 mM.
4. The swab sample nucleic acid releaser according to claim 1, It is characterized in that The mass concentration of SDS in the nucleic acid releasing agent is 0.005% to 0.05%.
5. The swab sample nucleic acid releaser according to claim 1, It is characterized in that The volume concentration of Triton 100 in the nucleic acid releasing agent is 2% to 6%, preferably 2% to 4%.
6. The swab sample nucleic acid releaser according to claim 1, It is characterized in that The enzyme protectant is selected from one or more of gelatin, tween 20 or betaine.
7. The swab sample nucleic acid releaser according to claim 1, It is characterized in that The content of the enzyme protectant in the nucleic acid releaser is 2% to 6%, preferably 4%.
8. The swab sample nucleic acid releaser according to claim 1, It is characterized in that The nucleic acid releaser has a strong base concentration of 10-20 mM, a SDS mass concentration of 0.008% to 0.012%, a Triton 100 mass volume concentration of 2% to 4%, and an enzyme protectant content of 2% to 6%.
9. The swab sample nucleic acid releaser according to claim 8, It is characterized in that The strong base in the nucleic acid releaser is NaOH, and the enzyme protectant is tween20.
10. The swab sample nucleic acid release agent according to claim 8, It is characterized in that The enzyme protectants are tween 20 and gelatin, and the mass ratio of the two is 4:0.2-0.6.
